112 related articles for article (PubMed ID: 38849758)
1. Predictive factors and adalimumab efficacy in managing chronic recurrence Vogt-Koyanagi-Harada disease.
Feng H; Chen W; Yang J; Kong H; Li H; He Y; Wang H
BMC Ophthalmol; 2024 Jun; 24(1):238. PubMed ID: 38849758
[TBL] [Abstract][Full Text] [Related]
2. Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of 'sunset glow fundus' in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; Dosari M; Hemachandran S; Gikandi PW; Al-Muammar A
Acta Ophthalmol; 2017 Feb; 95(1):85-90. PubMed ID: 27535102
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and Safety of Adalimumab for Exacerbation or Relapse of Ocular Inflammation in Patients with Vogt-Koyanagi-Harada Disease: A Multicenter Study.
Nakai S; Takeuchi M; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Ocul Immunol Inflamm; 2024 May; 32(4):367-375. PubMed ID: 35748779
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Clinical Features and Visual Outcome between Sympathetic Ophthalmia and Vogt-Koyanagi-Harada Disease in Chinese Patients.
Yang P; Liu S; Zhong Z; Du L; Ye Z; Zhou W; Kijlstra A
Ophthalmology; 2019 Sep; 126(9):1297-1305. PubMed ID: 30959067
[TBL] [Abstract][Full Text] [Related]
5. Chronic Recurrent Vogt-Koyanagi-Harada Disease and Development of 'Sunset Glow Fundus' Predict Worse Retinal Sensitivity.
Abu El-Asrar AM; Al Mudhaiyan T; Al Najashi AA; Hemachandran S; Hariz R; Mousa A; Al-Muammar A
Ocul Immunol Inflamm; 2017 Aug; 25(4):475-485. PubMed ID: 27003480
[TBL] [Abstract][Full Text] [Related]
6. Vitiligo as a First Sign of Vogt-Koyanagi-Harada Disease.
Vukojević M; Vukojevic N; Vuković A; Rupčić B; Blažević M; Blažević A
Acta Dermatovenerol Croat; 2023 Dec; 31(4):229-231. PubMed ID: 38651852
[TBL] [Abstract][Full Text] [Related]
7. Adalimumab treatment for chronic recurrent Vogt-Koyanagi-Harada disease with sunset glow fundus: A multicenter study.
Takeuchi M; Nakai S; Usui Y; Namba K; Suzuki K; Harada Y; Kusuhara S; Kaburaki T; Tanaka R; Takeuchi M; Mizuki N; Nakai K; Goto H; Herbort CP
Saudi J Ophthalmol; 2022; 36(4):380-386. PubMed ID: 36618573
[TBL] [Abstract][Full Text] [Related]
8. Clinical and Transcriptional Profiles Reveal the Treatment Effect of Adalimumab in Patients with Initial-Onset and Recurrent Vogt-Koyanagi-Harada Disease.
Guo K; Xu X; Yang F; Wang K; Zhang X
Ocul Immunol Inflamm; 2024 May; ():1-11. PubMed ID: 38709230
[TBL] [Abstract][Full Text] [Related]
9. Sunset glow fundus in Vogt-Koyanagi-Harada disease with or without chronic ocular inflammation.
Keino H; Goto H; Usui M
Graefes Arch Clin Exp Ophthalmol; 2002 Oct; 240(10):878-82. PubMed ID: 12397437
[TBL] [Abstract][Full Text] [Related]
10. Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids.
Abu El-Asrar AM; Al Tamimi M; Hemachandran S; Al-Mezaine HS; Al-Muammar A; Kangave D
Acta Ophthalmol; 2013 Sep; 91(6):e486-93. PubMed ID: 23575246
[TBL] [Abstract][Full Text] [Related]
11. Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids.
Nakayama M; Keino H; Watanabe T; Okada AA
Br J Ophthalmol; 2019 Feb; 103(2):274-278. PubMed ID: 29666121
[TBL] [Abstract][Full Text] [Related]
12. Incidence, Risk Factors and Surgical Outcomes of Cataract among Patients with Vogt-Koyanagi-Harada Disease.
AlBloushi AF; Alfawaz AM; AlZaid A; Alsalamah AK; Gikandi PW; Abu El-Asrar AM
Ocul Immunol Inflamm; 2021 Jan; 29(1):128-136. PubMed ID: 31638886
[No Abstract] [Full Text] [Related]
13. Adalimumab Treatment in Patients with Vogt-Koyanagi-Harada Disease.
Couto C; Schlaen A; Frick M; Khoury M; Lopez M; Hurtado E; Goldstein D
Ocul Immunol Inflamm; 2018; 26(3):485-489. PubMed ID: 27775450
[TBL] [Abstract][Full Text] [Related]
14. Retinal vessel oxygen saturation is affected in uveitis associated with Vogt-Koyanagi-Harada disease.
Abu El-Asrar AM; AlBloushi AF; Gikandi PW; Hardarson SH; Stefánsson E
Br J Ophthalmol; 2019 Dec; 103(12):1695-1699. PubMed ID: 30798260
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors in Vogt-Koyanagi-Harada disease.
Al-Kharashi AS; Aldibhi H; Al-Fraykh H; Kangave D; Abu El-Asrar AM
Int Ophthalmol; 2007; 27(2-3):201-10. PubMed ID: 17435968
[TBL] [Abstract][Full Text] [Related]
16. A Novel Risk Stratification-Based Immunomodulatory Treatment Strategy for Vogt-Koyanagi-Harada Disease.
Jin K; Liang A; Song H; Xiao F; Gao F; Han X; Zhang M; Zhao C
Am J Ophthalmol; 2024 Jun; 262():25-33. PubMed ID: 38369223
[TBL] [Abstract][Full Text] [Related]
17. A clinical grading system based on ultra-wide field retinal imaging for sunset glow fundus in Vogt-Koyanagi-Harada disease.
Lee EK; Lee SY; Yu HG
Graefes Arch Clin Exp Ophthalmol; 2015 Mar; 253(3):359-68. PubMed ID: 25017008
[TBL] [Abstract][Full Text] [Related]
18. Depigmented atrophic lesions in sunset glow fundi of Vogt-Koyanagi-Harada disease.
Inomata H; Rao NA
Am J Ophthalmol; 2001 May; 131(5):607-14. PubMed ID: 11336935
[TBL] [Abstract][Full Text] [Related]
19. Outcomes of initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease occurred during pregnancy.
Alromaih AZ; Almater AI; Albloushi AF; Alkheraiji NF; Abu El-Asrar AM
Int Ophthalmol; 2023 Jan; 43(1):185-195. PubMed ID: 35945413
[TBL] [Abstract][Full Text] [Related]
20. Choroidal observations in Vogt-Koyanagi-Harada disease using high-penetration optical coherence tomography.
Nakai K; Gomi F; Ikuno Y; Yasuno Y; Nouchi T; Ohguro N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2012 Jul; 250(7):1089-95. PubMed ID: 22240936
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
